Overview

Cysteamine Therapy for Major Depressive Disorder

Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
Phase:
N/A
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Murrough, James, M.D.
Collaborator:
Icahn School of Medicine at Mount Sinai
Treatments:
Cysteamine